Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.
A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis.
A
A
Fornasiero
O
O
Daniele
V P
VP
Fosser
A
A
Paccagnella
L
L
Salvagno
V C
VC
Sileni
P
P
Morandi
M V
MV
Fiorentino
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000031:analogs & derivatives*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010440:Peptichemio / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000517:prevention & control
D006493:Heparin; D010440:Peptichemio; D008558:Melphalan